Literature DB >> 30231724

Patient Voice in Rare Disease Drug Development and Endpoints.

Linda S Deal1, Jonathan C Goldsmith2, Susan Martin3, Ann J Barbier4, Steven L Roberds5, David H Schubert6.   

Abstract

While planning for a successful clinical trial in a prevalent condition is no trivial orchestration, even more complicated is the coordination of novel, delicate and critical operational components necessary for the successful conduct of clinical trials of rare disease (RD). We highlight some of the inherent and practical challenges to conducting clinical trials and selecting or developing endpoints for RD and the importance of including the patient voice or perspective. These challenges include the lack of regulatory precedent for proposed endpoints, a void of available measures, little or no published literature or natural history information, the practicalities of obtaining access to patients, and the appropriateness of placebo-controlled trials. As part of our review, we include practical considerations for addressing these issues along with a regulatory perspective regarding potential logistic and methodologic challenges. We conclude that the patient perspective is a critical component in defining treatment benefit and in interpreting the meaningfulness of a change (or lack thereof). Engaging with patients is needed at multiple steps along the long road of drug discovery.

Entities:  

Keywords:  drug development; endpoints; patient voice; patient-centered; rare disease

Year:  2016        PMID: 30231724     DOI: 10.1177/2168479016671559

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  2 in total

1.  Examining Physician Interactions with Disease Advocacy Organizations.

Authors:  Caroline Horrow; Joel E Pacyna; Carol Cosenza; Richard R Sharp
Journal:  AJOB Empir Bioeth       Date:  2019-08-26

Review 2.  GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy.

Authors:  Maya Chopra; Meera E Modi; Kira A Dies; Nancy L Chamberlin; Elizabeth D Buttermore; Stephanie Jo Brewster; Lisa Prock; Mustafa Sahin
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-29       Impact factor: 5.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.